Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Net Cash Flow (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Net Cash Flow for 6 consecutive years, with -$18.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 119310.81% year-over-year to -$18.5 million, compared with a TTM value of $1.8 million through Dec 2025, up 103.83%, and an annual FY2025 reading of $1.8 million, up 103.83% over the prior year.
  • Net Cash Flow was -$18.5 million for Q4 2025 at SAB Biotherapeutics, down from $25.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $54.1 million in Q4 2023 and bottomed at -$42.5 million in Q1 2024.
  • Average Net Cash Flow over 5 years is -$83557.6, with a median of -$2.7 million recorded in 2025.
  • The sharpest move saw Net Cash Flow skyrocketed 33841.08% in 2021, then crashed 119310.81% in 2025.
  • Year by year, Net Cash Flow stood at $28.8 million in 2021, then crashed by 76.68% to $6.7 million in 2022, then surged by 706.03% to $54.1 million in 2023, then crashed by 99.97% to $15539.0 in 2024, then plummeted by 119310.81% to -$18.5 million in 2025.
  • Business Quant data shows Net Cash Flow for SABS at -$18.5 million in Q4 2025, $25.8 million in Q3 2025, and -$2.1 million in Q2 2025.